Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2073-2079

  Marcolino, M S ^a   Boersma, E ^b   Clementino, N C D ^a   Macedo, A V ^a   Marx Neto, A D ^a   Silva, M H C R ^a   van Gelder, T ^b   Akkerhuis, K M ^b   Ribeiro, A L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute kidney injury; Adverse effects; Chronic renal failure; Drug induced nephrotoxicity; Imatinib; Protein kinase inhibitors

Indexed keywords

ALPHA INTERFERON; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYUREA; IMATINIB; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; UREA; URIC ACID; XANTHINE OXIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; BLAST CELL CRISIS; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; METAPHASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; REHYDRATION; THROMBOCYTE COUNT; TREATMENT DURATION; TUMOR LYSIS SYNDROME;

EID: 79960955609     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq715     Document Type: Article

References (40)

1. Pappas P, Karavasilis V, Briasoulis E et al. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005; 56: 358-360.
2. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
3. Blackstein ME, Blay JY, Corless C et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20: 157-163.
4. Vandyke K, Fitter S, Dewar AL et al. Dysregulation of bone remodelling by imatinib mesylate. Blood 2010; 115: 766-774.
5. Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002; 17: 685-687.
6. Foringer JR, Verani RR, Tjia VM et al. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005; 39: 2136-2138.
7. Pinder EM, Atwal GS, Ayantunde AA et al. Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with glivec (imatinib mesylate, Gleevec, STI571). Sarcoma 2007; 2007: 82012.
8. Al-Kali A, Farooq S, Tfayli A. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther 2009; 34: 607-610.
9. Pou M, Saval N, Vera M et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44: 1239-1241.
10. Vora A, Bhutani M, Sharma A, Raina V. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol 2002; 13: 1833-1834.
11. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008; 78: 743-750.
12. Gafter-Gvili A, Ram R, Gafter U et al. Renal failure associated with tyrosine kinase inhibitors-case report and review of the literature. Leuk Res 2010; 34: 123-127.
13. Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Target Oncol 2009; 4: 121-133.
14. Takikita-Suzuki M, Haneda M, Sasahara M et al. Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol 2003; 163: 277-286.
15. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
16. Hochhaus A, O'Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
17. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
19. Coresh J, Byrd-Holt D, Astor BC et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-188.
20. Ribeiro AL, Marcolino MS, Bittencourt HN et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 2008; 32: 1809-1814.
21. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526.
22. Soares AA, Eyff TF, Campani RB et al. Glomerular filtration rate measurement and prediction equations. Clin Chem Lab Med 2009; 47: 1023-1032.
23. Mehta RL, Kellum JA, Shah SV et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
24. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
25. Bash LD, Coresh J, Kottgen A et al. Defining incident chronic kidney disease in the research setting: the ARIC Study. Am J Epidemiol 2009; 170: 414-424.
26. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799.
27. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11.
28. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285.
29. TM: Chronic Myelogenous Leukemia Version 2.2010. JNCCN 2009; 7: 984-1023.
30. Martin JE, Sheaff MT. Renal ageing. J Pathol 2007; 211: 198-205.
31. Wetzels JF, Kiemeney LA, Swinkels DW et al. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 2007; 72: 632-637.
32. Lechner J, Malloth N, Seppi T et al. IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium. Am J Physiol Cell Physiol 2008; 294: C153-C160.
33. Vuky J, Isacson C, Fotoohi M et al. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 2006; 24: 85-88.
34. Ozkurt S, Temiz G, Acikalin MF, Soydan M. Acute renal failure under dasatinib therapy. Ren Fail 2010; 32: 147-149.
35. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838.
36. Launay-Vacher V, Oudard S, Janus N et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384.
37. Demetri GD. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest 2007; 117: 3650-3653.
38. Vega-Ruiz A, Cortes JE, Sever M et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33: 1481-1484.
39. David M, Cross NC, Burgstaller S et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61-64.
40. Gotlib J, Cools J, Malone JM et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891.